Anatara Lifesciences Ltd Total Liabilities

Latest as of June 2025: AU$612.42K AUD ≈ $433.33K USD

Anatara Lifesciences Ltd total liabilities. Based on the latest financial reports, Anatara Lifesciences Ltd (ANR) has total liabilities worth AU$612.42K AUD (≈ $433.33K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Anatara Lifesciences Ltd's assets to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Anatara Lifesciences Ltd (2011–2025)

Total liabilities of Anatara Lifesciences Ltd from 2011 to 2025. This chart illustrates how Anatara Lifesciences Ltd's total liabilities have evolved over time, based on quarterly financial data.

Anatara Lifesciences Ltd Competitors by Total Liabilities

The table below lists competitors of Anatara Lifesciences Ltd ranked by their total liabilities.

Company Country Total Liabilities
Savannah Energy PLC
LSE:SAVE
UK GBX1.33 Billion
GO2 People Ltd
AU:GO2
Australia AU$2.69K
Pineapple Financial Inc.
NYSE:PAPL
USA $3.86 Million
Hitek Global Inc.
NASDAQ:HKIT
USA $6.57 Million
Sonovia Ltd
TA:SONO
Israel ILA149.03K
True North Gems Inc
V:TGX
Canada CA$7.19 Million
Multipolar Tbk
JK:MLPL
Indonesia Rp8.06 Trillion
Innovation Beverage Group Limited
NASDAQ:IBG
USA $1.86 Million

Liability Composition Analysis (2011–2025)

This chart breaks down Anatara Lifesciences Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Anatara Lifesciences Ltd (ANR) total assets.

Liquidity & Leverage Metrics

Anatara Lifesciences Ltd Total Liabilities Ratios Explained

Anatara Lifesciences Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 1.89 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.14 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.53 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Anatara Lifesciences Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Anatara Lifesciences Ltd (2011–2025)

The table below shows the annual total liabilities of Anatara Lifesciences Ltd from 2011 to 2025.

Year Total Liabilities Change
2025-06-30 AU$612.42K
≈ $433.33K
+99.58%
2024-06-30 AU$306.85K
≈ $217.12K
-37.99%
2023-06-30 AU$494.83K
≈ $350.13K
+22.68%
2022-06-30 AU$403.35K
≈ $285.40K
-18.79%
2021-06-30 AU$496.67K
≈ $351.43K
+1.99%
2020-06-30 AU$486.96K
≈ $344.56K
+4.33%
2019-06-30 AU$466.76K
≈ $330.26K
-61.90%
2018-06-30 AU$1.22 Million
≈ $866.73K
+314.62%
2017-06-30 AU$295.44K
≈ $209.04K
-33.55%
2016-06-30 AU$444.62K
≈ $314.60K
+202.51%
2015-06-30 AU$146.98K
≈ $104.00K
-35.43%
2014-06-30 AU$227.62K
≈ $161.05K
-35.51%
2013-06-30 AU$352.96K
≈ $249.74K
+141.75%
2012-06-30 AU$146.00K
≈ $103.30K
+630.00%
2011-06-30 AU$20.00K
≈ $14.15K
--

About Anatara Lifesciences Ltd

AU:ANR Australia Biotechnology
Market Cap
$1.40 Million
AU$1.98 Million AUD
Market Cap Rank
#30384 Global
#1775 in Australia
Share Price
AU$0.01
Change (1 day)
+0.00%
52-Week Range
AU$0.01 - AU$0.01
All Time High
AU$1.64
About

Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in Australia. The company's products include Gastrointestinal ReProgramming, a multi-component, multi-coated medicine designed to address underlying factors associated with chronic gastrointestinal conditions, such as irritable bowel syndrome and inflammat… Read more